NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Parallel Bio

Parallel Bio

Private
Brisbane, CaliforniaHealthcare & Life Scienceshttps://www.parallel.bio/

Last Round

Series A

Jun 12, 2025

Total Funding Raised

$25.43M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Parallel Bio is a biotechnology company that pioneers human-first drug discovery by combining immune organoids with artificial intelligence to replicate the human immune system for testing immunotherapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

organ-on-a-chipdrug discoveryimmune system-on-a-chipclinical trial in a dishpreclinical researchimmune organoidbiotech servicesdrug developmentpredictive biologyhuman biology atlasde-risking drug developmentin vitro testingfood and drug administrationFDAbiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Parallel Bio Comparables

Compare Parallel Bio with similar companies based on industry and business-model similarity.

Parallel Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Parallel Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 12, 2025
SeedDec 20, 2022
SeedSep 1, 2021

Key People

Founding team and executive leadership

Robert M. DiFazio

Co-Founder CEO

Founding Team

Parallel Bio Investors

Notable investors and investment history

Parallel Bio investors
InvestorRounds
Refactor CapitalSeed
AtypicalSeries A
AmploSeries A
Metaplanet HoldingsSeries A
Breakout VenturesSeed
Humba VenturesSeries A
Y CombinatorSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Data supports partner's FDA filing for Phase 1 trial.

  • Mar 1, 2026

    Executed 10 pharma contracts with strong year-over-year revenue growth.

Parallel Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Parallel Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Parallel Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBrisbane, California
Employee Range27
Year Founded2021
Last FundingJun 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.